Bioxytran, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 10, 2021 at 10:02 am EDT
Share
Bioxytran, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 1.042 million compared to USD 111,909 a year ago. Net loss was USD 896,701 compared to USD 928,598 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the half year, operating loss was USD 2.731 million compared to USD 377,952 a year ago. Net loss was USD 2.518 million compared to USD 1.469 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
BIOXYTRAN, INC. 
